Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.46
- Piotroski Score 3.00
- Grade Overweight
- Symbol (VXRT)
- Company Vaxart, Inc.
- Price $0.60
- Changes Percentage (0.65%)
- Change -$0
- Day Low $0.59
- Day High $0.62
- Year High $1.54
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
- Last Earnings 10/25/2012
- Ex-Dividend for 5/16 Dividend 11/09/2012
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.52
- Trailing P/E Ratio -1.48
- Forward P/E Ratio -1.48
- P/E Growth -1.48
- Net Income $-82,465,000
Income Statement
Quarterly
Annual
Latest News of VXRT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most
Retail investors have significant control over Vaxart, giving them influence on management decisions. Institutions own 11%, while hedge funds have no substantial investment. The general public holds 5...
By Yahoo! Finance | 5 months ago -
Vaxart, Inc. (VXRT) Stock Price, News, Quote & History - Yahoo Finance
Vaxart, Inc. is a biotech company focusing on oral recombinant protein vaccines. They are developing vaccines for norovirus, coronavirus, seasonal influenza, and HPV, with products in various stages o...
By Yahoo! Finance | 5 months ago
